ライフサイエンスコーパス: initial presentation

1 least one definite CCM and 134 were alive at initial presentation.

2 collected and easily obtained at the time of initial presentation.

3 farther from the reference point during its initial presentation.

4 time of phlebotomy, on average 4 hours from initial presentation.

5 to clinical deterioration 7 to 10 days after initial presentation.

6 e stimulus that had lasted longer during its initial presentation.

7 nd recurrent ACS were assessed 30 days after initial presentation.

8 ce rate for ABS was 11.4% over 4 years after initial presentation.

9 remained free of tumor for 5 years after the initial presentation.

10 ity to or with the same localizations as the initial presentation.

11 P) had been considered in all three cases at initial presentation.

12 tion who had cTnI assay drawn at the time of initial presentation.

13 8%) completed a questionnaire 3 months after initial presentation.

14 patients had positive CMV IgG serologies at initial presentation.

15 chest radiographs and CT images available at initial presentation.

16 ed a simplified fast-track screen for use at initial presentation.

17 lood specimens obtained from all patients at initial presentation.

18 ity vasculitis on the basis of the patients' initial presentation.

19 ay in resuscitation, or laboratory values on initial presentation.

20 s, leukemia cutis, or meningeal leukemia) at initial presentation.

21 atient with angiographically-confirmed PE at initial presentation.

22 ropriately evaluated and managed after their initial presentation.

23 sually affected the same organ systems as on initial presentation.

24 he left hip was performed 4 months after the initial presentation.

25 gery at a mean duration of 18.1 months after initial presentation.

26 vitreal vancomycin-ceftazidime injections at initial presentation.

27 ontrast material approximately 8 hours after initial presentation.

28 male: 249/53) with CSC were evaluated on the initial presentation.

29 MRI (Fig 3) was performed 2 months after the initial presentation.

30 c spine MRI was performed 2 months after the initial presentation.

31 but infection presence is often uncertain at initial presentation.

32 rs at disease onset and 9.3 years at time of initial presentation.

33 en when treatment is within a few days after initial presentation.

34 ens, and clinical outcomes 14 days after the initial presentation.

35 ancreatic function, with varying severity of initial presentation.

36 cording to persisting symptoms as opposed to initial presentation.

37 antation occurred in 13% within 2 decades of initial presentation.

38 ative CT images of 364 EOC patients at their initial presentation.

39 5 years, and depression is the most frequent initial presentation.

40 jority of eyes with iERM remain stable after initial presentation.

41 which was similar in severity compared with initial presentation.

42 ch was similar in severity compared with the initial presentation.

43 ere classified as non-metastatic (M0) at the initial presentation.

44 ent, if the latter were within 14 days after initial presentation.

45 factors that predispose to persistent AF on initial presentation.

46 me) in STEC-infected children without HUS at initial presentation.

47 morrhagic and nonhemorrhagic groups based on initial presentation.

48 odies (ANA) and ANA subsets were obtained at initial presentation.

49 ve disease persisting more than 90 days from initial presentation.

50 peat ED visits and hospital admissions after initial presentation.

51 penia, and hyponatremia were often absent at initial presentation.

52 after stabilization and again 30 days after initial presentation.

53 ecurrence are linked to the primary tumor at initial presentation.

54 pathogen-related differences in symptoms at initial presentation.

55 rological symptoms have been described after initial presentation.

56 ies were obtained 3 months and 4 years after initial presentation.

57 efined epitopes approximately 2 months after initial presentation.

58 case of PALG with hyperopic shift and CFs as initial presentation.

59 d for device activation within 90 minutes of initial presentation.

60 l discriminations for repeated compared with initial presentations.

61 gnostic uncertainty at the time of patients' initial presentations.

62 d platelet counts are relatively uncommon in initial presentations.

63 eturn to the ED for AF within 30 days of the initial presentation (1.6% to 2.7%; hazard ratio, 1.70 [

64 Those with follow-up within 6 months of initial presentation (228 patients, 246 unique encounter

65 At initial presentation, 25% of patients (12% N1, 11% N2, a

66 In 80% of eyes with RD at initial presentation (28/35 eyes), the retina remained c

67 52%] female) aged 2 to 18 years (mean age at initial presentation, 28 months; range, 0-121 months) we

68 .5); P = 0.041] and altered consciousness at initial presentation [3.0 (1.3-6.7); P = 0.0077] were as

69 37.5%, P = 0.061), have liver failure at the initial presentation (37.8% versus 9.3%, P = 0.001), and

70 On initial presentation, 6/32 (19%) had an amblyogenic refr

71 On initial presentation, 95 (48.2%) patients reported skin

72 Upon initial presentation, a full periodontal examination was

73 , most patients improved within 1-2 weeks of initial presentation after vaping cessation and administ

74 On the initial presentation, age, subfoveal choroidal thickness

75 The age and gender of each participant upon initial presentation, along with biological parameters,

76 vided to sepsis and septic shock patients at initial presentation and 2) determine the association be

77 (TCR) repertoire in aplastic anemia (AA) at initial presentation and after immunosuppression using a

78 ciated with severe visual impairment both at initial presentation and after treatment.

79 therapy (ECT) on two separate occasions: on initial presentation and again a year later when the pat

80 Twenty-four patients were asked at initial presentation and at 30 days to grade their sever

81 pharmacological treatment decisions both at initial presentation and at follow up.

82 gH CDRII region was identical at the time of initial presentation and at relapse suggesting that clon

83 who did not have bone marrow involvement at initial presentation and at time of the procedure, albei

84 potency of these responses in patients upon initial presentation and before treatment, we determined

85 ion and level of evidence in the approach to initial presentation and diagnosis of NSTE-ACS, risk ass

86 l information was systematically gathered at initial presentation and during follow-up.

87 ed scenes that were attended both during the initial presentation and during repetition.

88 ribe the abdominal US features of PIMS-TS at initial presentation and follow-up.

89 US features were documented and reviewed at initial presentation and follow-up.

90 is of anterior uveitis within 90 days before initial presentation and had follow-up visits thereafter

91 asciitis is often confused for cellulitis at initial presentation and is considered to be more severe

92 ic yield and corrected visual acuity (VA) at initial presentation and last follow-up (up to 1 year) w

93 on, was performed to study correlations with initial presentation and outcomes.

94 ion of repeating the RPR titer if the day of initial presentation and the day of treatment are differ

95 ho underwent syphilis serology on the day of initial presentation and the day of treatment, if the la

96 nitoring was significantly influenced by the initial presentation and the distribution of blood obser

97 rld Health Organization criteria at both the initial presentation and the final follow-up visit.

98 ealth-care disparities contribute to delayed initial presentation and timely repair.

99 come of the consecutive NAION event based on initial presentation and to compare mean visual loss of

100 in RPR titer, stratified by the time between initial presentation and treatment and by syphilis stage

101 syphilis cases, the median duration between initial presentation and treatment was 6 days (interquar

102 titer increased with increasing time between initial presentation and treatment, from 5.7% (n = 6) 1-

103 collected and analyzed information regarding initial presentations and final outcomes in patients dia

104 as to analyze the characteristic features of initial presentations and final outcomes of PPLA caused

105 centage of questions answered correctly upon initial presentation) and completion scores (percentage

106 233 (86.1%) were transferred the same day as initial presentation, and 1897 (73.2%) received antibiot

107 d conditions, complicated biliary disease on initial presentation, and initial presentation to the em

108 psies of test cohorts was performed at their initial presentation, and those spontaneously eliminatin

109 ith AIH, have more aggressive disease at the initial presentation, are less likely to respond to conv

110 Patients were identified according to initial presentation as having localized or multicentric

111 istologic examination and wound culture from initial presentation as well as clinical follow-up docum

112 ent, we used data available during patients' initial presentation at the emergency department (ED) to

113 osed with definite IE within the 12 weeks of initial presentation based on modified Duke criteria.

114 iagnosed with definite IE within 12 weeks of initial presentation based on modified Duke's criteria.

115 ) had cochleovestibular dysfunction as their initial presentation before rhombencephalitis/encephalom

116 ference in glaucoma or suspect prevalence at initial presentation between eyes treated with injection

117 a history of RT or RRD in the fellow eye at initial presentation but only 0.7% of patients without a

118 Endotoxemia was not evident on initial presentation, but developed subsequently in 75%

119 nistered at 3, 6, 9, and 12 months following initial presentation, by telephone or in person.

120 Initial presentation can be asymptomatic; however, many

121 Several clinical variables at the time of initial presentation can predict the future risk of deta

122 in patients with lacrimal involvement as the initial presentation, can be difficult because of nonspe

123 patients at risk for malnutrition regarding initial presentation, clinical outcomes, and treatment r

124 e weakness (50%) and muscle atrophy (67%) at initial presentation compared with antisynthetase-positi

125 t an immunodeficiency with a clinically mild initial presentation could be a combined immunodeficienc

126 Analysis of serum from initial presentation demonstrated biphasic hemolysis, co

127 tients, 13 (26%) were correctly diagnosed at initial presentation; diagnosis was delayed, on average,

128 At the time of initial presentation, DNA from patients with CLL was pol

129 ascular conditions among patients with AN at initial presentation, during treatment, and at follow-up

130 record review (length of symptoms; times of initial presentation, emergency department (ED) triage,

131 ht, gestational age at birth, bicarbonate at initial presentation, feeding type, preoperative duratio

132 On the initial presentation, female patients were significantly

133 of the left hip was performed 4 months after initial presentation (Fig 4).

134 pect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endo

135 f clinically recorded neutrophil counts with initial presentation for a range of CVDs.

136 ed several but not all of her NHPs after her initial presentation for acute hepatitis at the first in

137 .2%) underwent appendectomy within 1 year of initial presentation for appendicitis.

138 aphics, clinical, and laboratory measures on initial presentation for FN.

139 a visual acuity of 20/200 at 6 months after initial presentation for the NVG arm.

140 visual acuity of <=20/200 at 6 months after initial presentation for the NVG arm.

141 Patients aged < 40 years at the initial presentation had a 3.8 times higher risk of bila

142 Patients with typical AD and non-amnesic initial presentation had a significantly higher ratio of

143 ion of that shape, regardless of whether its initial presentation had been supraliminal or subliminal

144 distant-stage (metastatic) breast cancer at initial presentation has increased significantly in U.S.

145 and severity of heart failure at the time of initial presentation have been formally categorized by t

146 These variations in initial presentation have important clinical consequence

147 Thirteen days after initial presentation, he became febrile and had signs of

148 Extra-adrenal oligometastatic disease at initial presentation (HR: 1.84, P = 0.016), larger tumor

149 d as quiescence of disease within 90 days of initial presentation, HZO recurrence was defined as any

150 art tuberculosis treatment within 2 weeks of initial presentation if all required consumables were av

151 At initial presentation, imaging of the spine and spinal ca

152 [Table: see text] At initial presentation, imaging of the spine and spinal ca

153 up that underwent surgery within 6 months of initial presentation ("immediate surgery").

154 Papilledema was present on initial presentation in 54% of patients or detected late

155 Ophthalmologic involvement was part of the initial presentation in 69% of patients (22/32).

156 5P mutation during vitreous biopsy or at the initial presentation in the clinic if vitreous biopsy wa

157 silent or masked choroid, and a mean age at initial presentation in the third decade.

158 Psychiatric symptoms are prominent in the initial presentation in these cases.

159 The SD-OCT features more commonly seen at initial presentation in VRL patients (vs.

160 ed glaucoma screening efforts, since delayed initial presentation is a major risk factor for vision l

161 Their initial presentation is acute, with a few days to weeks

162 es, along with a high degree of suspicion on initial presentation is crucial in order to provide the

163 cess but the detection of CTC at the time of initial presentation is not necessarily a poor prognosti

164 insufficiency is usually delayed because the initial presentation is often non-specific; physician aw

165 We found medium concordance for testing at initial presentation (k = 0.68) and very low concordance

166 proliferation caused by its multifocality at initial presentation, lack of aneuploidy, and spontaneou

167 ection of the primary sites months after the initial presentation, light microscopy, and comprehensiv

168 festations may develop many months after the initial presentation, mandating the need for long-term f

169 ) and to describe to what extent a patient's initial presentation may be predictive of encephalitis e

170 at the final visit after treatment than the initial presentation (median CMT 332,5u versus 234u, p <

171 On initial presentation, men were a decade older (61 vs 50

172 Patients with mild iERM at initial presentation METHODS: A retrospective study with

173 At the initial presentation, NICCD patients had higher levels o

174 ing a multivariate analysis, was symptoms at initial presentation (odds ratio [95% confidence interva

175 mTBI with complete 30-day data and a median initial presentation of 90 minutes after injury, those w

176 f a pre-existing neurological condition, the initial presentation of a non-pregnancy-related problem,

177 stigate a pattern of association between the initial presentation of a patient and the etiologic path

178 A 2-year lookback period from the date of initial presentation of AACC was used to identify patien

179 basis of nonischemic FFR in patients with an initial presentation of ACS is associated with significa

180 Immunologic priming (initial presentation of an antigen to allow antibody res

181 Rheumatic manifestations may often be the initial presentation of an endocrine disorder.

182 of FA is likely facilitated by the improper initial presentation of antigen to the developing immune

183 ciation between a panel of blood proteins at initial presentation of bacteremia and disease severity

184 compared cumulative incidence curves for the initial presentation of cardiovascular disease and used

185 fluid samples collected from children during initial presentation of central nervous system inflammat

186 vationProcedure: Baseline characteristics at initial presentation of children with PCG in the registr

187 ar hypokinesis without dilation could be the initial presentation of dilated cardiomyopathy.

188 sentation of rheumatic manifestations is the initial presentation of endocrine disease.

189 Ophthalmic manifestations could be the initial presentation of human mpox and could also be sev

190 The initial presentation of hypertension during pregnancy in

191 ated encounters included healthy children at initial presentation of illness.

192 litis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transve

193 In this article, a patient whose initial presentation of lymphoma was the sudden onset of

194 ses without intestinal manifestations as the initial presentation of NSAID-induced colitis.

195 time between exposure to gadolinium and the initial presentation of NSF is typically weeks to months

196 Increased concentrations of BNP at initial presentation of patients with STEMI are associat

197 Use of 18F-FDG-PET/CT at the initial presentation of patients with suspected PVE incr

198 nal detachment cases with primary PVR at the initial presentation of RD were more likely to undergo s

199 Uveitis was the initial presentation of sarcoidosis in the vast majority

200 We conclude that the initial presentation of sarcoidosis is related to sex, r

201 It is uncommon as initial presentation of the disease and can lead to extr

202 autoimmune diseases are characterized by the initial presentation of the disease being the most sever

203 without neurological involvement) either as initial presentation of the disease or as relapse are un

204 symptoms are not only common, but may be the initial presentation of this systemic inflammatory proce

205 asmatic tuberculomas were not present at the initial presentation of tuberculosis and appeared on bra

206 The majority of initial presentations of CVD are neither myocardial infa

207 Initial presentations of novel song (but not tones or no

208 ht the need for psychiatrists to be aware of initial presentations of paraneoplastic disorders.

209 Although the initial presentations of PPLA caused by different pathog

210 placed on the pediatric population, because initial presentations often occur during childhood.

211 Working groups focused on initial presentation, ongoing management, and empiric an

212 Results Recommendations related to initial presentation, ongoing management, and empirical

213 obtained from 28 patients with ES or PNET at initial presentation or at relapse.

214 rectly related to the underlying malignancy (initial presentation or progressive disease), to its tre

215 96 [95% CI, 0.61-1.52]) or at 3 months after initial presentation (OR, 1.26 [95% CI, 0.78-2.04]).

216 tudied, 36 (22%) had TE disease confirmed at initial presentation (PE = 19; DVT only = 17), and four

217 tation (when available), patient symptoms at initial presentation, physical examination findings, ana

218 Additional markers at initial presentation predictive of thrombosis during hos

219 h severe COVID-19 and sBSI had a more severe initial presentation, prolonged hospital course, and wor

220 Eighteen months post initial presentation ptosis and eye movements returned n

221 Recommendations were made related to initial presentation (risk stratification, initial evalu

222 Five athletes (7.2%) considered normal on initial presentation subsequently expressed pathology du

223 rmal, 16 patients; LOH, 2 patients) as their initial presentation, suggesting, albeit with a small pa

224 One month after initial presentation, symptoms worsened.

225 At initial presentation, the median CTG expansion size was

226 Nine months after initial presentation, the patient developed an impending

227 After nine months of initial presentation, the patient developed another RAM.

228 Two months after initial presentation, the patient developed neovasculari

229 Five days after initial presentation, the patient presented again to the

230 Among patients with haemorrhage at initial presentation, the risk of haemorrhage fell from

231 treatment, from 5.7% (n = 6) 1-3 days after initial presentation to 26.2% (n = 27) at 10-14 days (Pt

232 presentation without abrupt or any pain, and initial presentation to a nontertiary care hospital (all

233 Clinical information extended from initial presentation to death.

234 and blood panel profile data at the time of initial presentation to develop machine learning algorit

235 were offered a full 28-day course of PEP at initial presentation to healthcare, with fewer refusals

236 evere injuries is positively associated with initial presentation to high-volume trauma hospitals.

237 ents with systemic vasculitis increased from initial presentation to last observation by a median sco

238 Median interval from initial presentation to LR was 85 months.

239 re is recommended for at least 72 hours from initial presentation to maximize the potential for recov

240 The mean interval from initial presentation to onset of vitiligo was 77 months

241 se-induced leg pain questionnaire, time from initial presentation to surgery, and whether a patient h

242 sted, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics.

243 unger (nonelderly) patients with COVID-19 at initial presentation to the emergency department (ED); o

244 aracteristics that were readily available at initial presentation to the emergency department.

245 biliary disease on initial presentation, and initial presentation to the emergency department.

246 ing outcomes at 24 and 72 h from the time of initial presentation to the emergency room, and it provi

247 ately based on the ophthalmic examination on initial presentation to the hospital.

248 e, ranging from 6/7.5 to light perception on initial presentation to the oncology service.

249 s with chronic lymphocytic leukemia (CLL) at initial presentation to University of Texas M.D. Anderso

250 astatic) were unrelated to clinical stage at initial presentation, treatment history, or histopatholo

251 f DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent org

252 BCVA at the initial presentation visit was compared to BCVA at the t

253 At initial presentation, vitreous hemorrhages were present

254 tance Best corrected visual acuity (BCVA) at initial presentation was 0.36 +/- 0.29logMAR and at last

255 The median BCVA at the initial presentation was 0.6 logMAR (20/80 Snellen), and

256 et was 8.2 (3.6) years, the mean (SD) age at initial presentation was 10.4 (3.6) years, and 66 (55.5%

257 the adjusted hazard ratio for haemorrhage at initial presentation was 13.9 (95% CI 2.6-73.8; p=0.002)

258 The median age at initial presentation was 72.5 years, and 33.3% were men.

259 al visit, a high degree of vitreous cells at initial presentation was associated with a lower inciden

260 The initial presentation was more severe than in known types

261 Elevated D-dimer at initial presentation was predictive of coagulation-assoc

262 Initial presentation was treated with steroids (n = 30;

263 Focusing on the variables that describe the initial presentation, we performed a factor analysis of

264 Variables at initial presentation were evaluated for their prognostic

265 3 with inflammatory-distributive features at initial presentation were excluded, leading to a cohort

266 Low physical activity scores at the initial presentation were followed by high perceived str

267 medical records and SD-OCT images at time of initial presentation were reviewed in patients with biop

268 ermore, different potentials recorded during initial presentations were indicative of perceptual lear

269 Initial presentations were most commonly either musculos

270 e patients were studied 30 years after their initial presentation with a clinically isolated syndrome

271 Within 6 months of initial presentation with a necrotizing ulcerative gingi

272 reated aortic segments is precipitated by an initial presentation with AAD.

273 uidelines suggest 12 months of DAPT after an initial presentation with ACS.

274 blast cells from 104 consecutive children at initial presentation with acute lymphoblastic leukemia (

275 rs; OR, 6.38; 95% CI, 1.35-30.16; P = .009), initial presentation with bilateral ocular involvement (

276 ospectively followed cohort of children from initial presentation with either multiple sclerosis or m

277 The initial presentation with erythema nodosum and periarthr

278 Furthermore, initial presentation with heart failure may be a good pr

279 acco use [1.40 (1.18-1.66)]; and complicated initial presentation with obstruction [1.33 (1.06-1.65)]

280 Given the early onset of symptoms and the initial presentation with pulmonary embolism in some fam

281 ive protein (hs-CRP), for risk assessment at initial presentation with ST-segment elevation myocardia

282 apid plasma reagin (RPR) titer on the day of initial presentation with that on the day of syphilis tr